Markets

Bio-Rad Laboratories announced the death of its co-founder and Director Emeritus, Alice N. Schwartz, on September 25, 2025, at age 99. Founded in 1952, Bio-Rad grew from a specialty chemicals provider into a leading life science and clinical diagnostics company, driven by Schwartz’s technological contributions, including a pivotal thyroid function test kit. Her business acumen fostered innovation and scientific curiosity. Bio-Rad, with approximately 7,500 employees and $2.6 billion in revenue in 2024, continues to focus on innovative products for research and healthcare.

Sandstorm Gold’s acquisition by Royal Gold has secured key regulatory approvals, pending shareholder and court approvals, and Nasdaq listing. The deal, expected to close early Q4 2025, aims to diversify Royal Gold’s portfolio and enhance growth. Analysts foresee potential synergies from combining Royal Gold’s infrastructure with Sandstorm’s royalty portfolio, leading to cost efficiencies and greater financial capacity. Sandstorm shareholders are urged to vote on the arrangement by October 7, 2025, with online voting encouraged due to potential postal disruptions. Sandstorm holds interests across 40 operating mines and has approximately 230 royalties.

Progress Software (PRGS) announced strong Q3 2025 results, exceeding expectations with 40% revenue growth to $250 million and a 47% increase in Annualized Recurring Revenue (ARR) to $849 million. Non-GAAP diluted EPS rose 19% to $1.50. The company raised its full-year guidance and highlighted the successful integration of ShareFile. Progress is investing in AI, including agentic RAG technology. The Board increased the share repurchase authorization by $200 million. The company expects continued revenue and earnings growth.

Nextech3D.AI (NEXCF) aims to disrupt the $85 billion ticketing market with a blockchain platform. They leverage an existing network of 500+ event organizers to offer verifiable tickets with controlled resale and reduced fees. The company’s CEO, Evan Gappelberg, discussed this strategic shift after a six-month stock surge. The blockchain solution aims to combat fraud and high costs but faces competition and adoption challenges.

Rezolve Ai (RZLV) refuted a report by Fuzzy Panda Research, a firm shorting RZLV stock, calling it a manipulation attempt. CEO Wagner defended partnerships with Microsoft, Google, and Tether, reaffirming revenue figures validated by audits and SEC filings. The company highlighted its *brainpowa* AI platform and patents. Rezolve will address concerns at its October 1, 2025, earnings announcement.

SonicStrategy Inc. announced Dustin Zinger as CEO, replacing Mitchell Demeter who becomes Executive Chair and CEO of Sonic Labs. This aims to strengthen validator operations and network growth. The company also commenced trading on the Frankfurt Stock Exchange and initiated a €100,000 marketing campaign to target European investors. The leadership shift and expanded market presence are designed to accelerate growth in the blockchain validation market.

Chipotle is launching Red Chimichurri, a limited-time offering, in the U.S. and Canada on September 30th to attract Gen Z and differentiate itself in the fast-casual market. This vibrant sauce, featuring roasted garlic, cilantro, chili peppers, and citrus, complements dishes like Carne Asada. Chipotle Rewards members get a free sample on launch day. This move builds on previous successful limited-time items and reflects Chipotle’s focus on flavor innovation and culinary development. The company recommends pairing Red Chimichurri with select entrees.

Nordic American Tankers (NAT) will hold its Annual General Meeting (AGM) on November 21, 2025. The record date for shareholder voting eligibility is September 12, 2025. The Notice of Meeting and Proxy Statement will be filed with the SEC via Form 6-K after market close on September 29, 2025. Shareholders will receive detailed information about the meeting and voting procedures.

Murex and AWS are expanding their partnership, integrating Murex’s MX.3 platform as managed services on AWS. This offers financial institutions enhanced functionality, security, and operational excellence. The collaboration focuses on accelerating deployment and upgrades, expanding Murex’s SaaS offering (MXSaaS) and cloud-native XVA as a Service leveraging AWS’s scalability. MXSaaS has already gained four new customers since June. Murex is investing heavily in scaling MXSaaS operations. The aim is to provide agility, flexibility, and resilience, optimizing the client experience.

Genmab will acquire Merus for $97.00 per share in cash, a deal valued at approximately $8.0 billion. This acquisition adds petosemtamab, a late-stage asset with Breakthrough Therapy Designations for head and neck cancer, to Genmab’s portfolio. Petosemtamab has shown promising Phase 2 data and is currently in Phase 3 trials. Genmab anticipates the acquisition accelerating its business model transition, broadening revenue streams and being accretive to EBITDA by the end of 2029. The deal is expected to close in early 2026, pending customary approvals.